ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues

作者：Rodney John Hicks, Dik J. Kwekkeboom, Eric P. Krenning, Lisa Bodei, Simona Grozinsky‐Glasberg, Rudolf Arnold, Ivan Borbath, Jarosław Bogdan Ćwikła, Christos Toumpanakis, Gregory Kaltsas, Philippa Davies, Dieter Hörsch, Eva Tiensuu Janson, John Keith Ramage, all other Antibes Consensus Conference participants · 发表于：Neuroendocrinology · 年份：2017 · DOI：10.1159/000475526 · 被引用次数：343 · 研究领域：Neuroendocrine Tumor Research Advances、Lung Cancer Research Studies、Radiopharmaceutical Chemistry and Applications

The purpose of these guidelines is to assist physicians caring for patients with neuroendocrine neoplasia in considering eligibility criteria for peptide receptor radionuclide therapy (PRRT) and in defining the minimum requirements for PRRT. It is not these guidelines' aim to give recommendations on the use of specific radiolabelled somatostatin analogues for PRRT as different analogues are being used, and their availability is governed by varying international regulations. However, a recent randomized controlled trial, NETTER-1, has provided evidence that may establish 177Lu-DOTA-octreotate (LutaThera®) as the first widely approved agent. It also makes recommendations on what minimal patient, tumour, and treatment outcome characteristics should be reported for PRRT to facilitate robust comparisons between studies.